ABT financials
Abbott Laboratories · end-of-day data as of Oct 16, 2026
Abbott Laboratories
$104.89+2.4%
Buy · 29 analystsPT $122.35 +16.6%
ABT reported revenue of $12.59B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 13.0% from a year earlier. It posted diluted EPS of $0.53, free cash flow of $2.89B and a net margin of 7.4%.
Valuation
- P/E33.7x
- P/E vs own+24.7%
- P/E vs sector+19.8%
- FCF yield+4.8%
- Market cap$181B
Quarterly results
Q2 FY2026: Revenue +13.0% year over year, free cash flow 22.9% of revenue, operating margin 14.2%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $12.59B | 0.53 | $2.89B | 58.0% | 14.2% | 7.4% |
| Q1 FY2026 | Mar 31, 2026 | $11.16B | 0.62 | $916M | 56.3% | 16.5% | 9.6% |
| Q4 FY2025 | Dec 31, 2025 | $11.46B | 1.02 | $2.63B | 57.0% | 19.6% | 15.5% |
| Q3 FY2025 | Sep 30, 2025 | $11.37B | 0.94 | $2.29B | 55.7% | 18.1% | 14.5% |
| Q2 FY2025 | Jun 30, 2025 | $11.14B | 1.01 | $1.54B | 56.4% | 18.4% | 16.0% |
| Q1 FY2025 | Mar 31, 2025 | $10.36B | 0.76 | $933M | 52.6% | 16.3% | 12.8% |
| Q4 FY2024 | Dec 31, 2024 | $10.97B | 5.27 | $2.15B | 51.0% | 18.1% | 84.1% |
| Q3 FY2024 | Sep 30, 2024 | $10.63B | 0.94 | $2.15B | 51.0% | 17.1% | 15.5% |
| Q2 FY2024 | Jun 30, 2024 | $10.38B | 0.74 | $1.43B | 51.1% | 16.2% | 12.5% |
| Q1 FY2024 | Mar 31, 2024 | $9.96B | 0.70 | $627M | 50.4% | 13.9% | 12.3% |
| Q4 FY2023 | Dec 31, 2023 | $10.24B | 0.91 | $2.28B | 51.3% | 18.2% | 15.6% |
| Q3 FY2023 | Sep 30, 2023 | $10.14B | 0.82 | $1.32B | 49.6% | 16.5% | 14.2% |